Century Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Century Therapeutics, Inc. on June 12, 2025. The meeting was conducted virtually. As of the record date of April 16, 2025, there were 86,158,758 outstanding shares of common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1 - Election of Class I Directors:
- Daphne Quimi: Elected with 52,593,454 votes For, 4,437,555 Withheld, and 15,072,004 Broker Non-Votes.
- Carlo Rizzuto, Ph.D.: Elected with 51,373,990 votes For, 5,657,019 Withheld, and 15,072,004 Broker Non-Votes.
- Proposal 2 - Ratification of Independent Registered Public Accountant:
- Ernst & Young LLP was ratified for the 2025 fiscal year.
- Votes: 71,768,193 For, 302,484 Against, 32,336 Abstentions, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of newly elected directors Daphne Quimi and Carlo Rizzuto, Ph.D., who serve until the 2028 Annual Meeting.
- Confirm the significant number of Broker Non-Votes (15,072,004) recorded for the director elections.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 22, 2025, for detailed background on the proposals.